The complaint, captioned Robbins v. GRAIL, Inc., et al., asserts that the company violated the Securities Exchange Act of 1934 by issuing overly optimistic statements about the Galleri test. While the firm touted the trial’s ability to reduce late-stage cancer diagnoses, the project failed to meet its primary endpoint of statistically significant Stage III-IV reduction.

On February 19, 2026, GRAIL disclosed the trial’s failure, attributing the result to an insufficient follow-up period. The disclosure wiped out more than half of the company’s market value overnight, with shares falling from $101.53 to $50.21. Bleichmar Fonti & Auld LLP, the firm representing the class, is now seeking to hold senior executives accountable for the alleged misrepresentations. Investors wishing to serve as lead plaintiffs must file with the court by August 4, 2026.